 Today I have the pleasure of speaking to scientist and visionary Dr. Horst serve from Intelligenics Technologies. How are you today sir? I'm very good and thank you for having me. And I just have to ask you, when I have someone who is an inventor for all intents purposes as scientist, visionary like yourself, what was behind you coming up with this the verse of film? As a scientist working in drug delivery, our main objective is to improve the efficacy of it and its availability in the body. That's what drug delivery is all about. And the film technology is just one very actually very exciting tool to achieve rapid onset of action, which is one of the objectives of somebody working in drug delivery, and to improve the availability and increase the concentration of the drug indigo. Those are the two main objectives that prompted us to come up with the verse of film. So Dr. Sir, when you say we, it's my understanding that you are the inventor. I see that you're sharing this credit with other people. Were you sitting at the dinner table with your young children going if only I could get put this food under their tongue and administer these vitamins. Can I, can I ask you to take this one step further and tell us how you really had the inspiration for this technology? You know what? The time of the Einstein's inside is gone. You know, science is teamwork. And I have, let me say, the great fortune to be surrounded by a pretty brilliant team of scientists here at Intelligenics. And so we as a team came up with this. But I really, it would not be right if I took all the credit for this. There's a great team standing behind us. So Dr. Sir, Montelukest, it's all over the Intelligenics website. Can you tell us why you're so excited about this project? Sure. We discovered Montelukest as a great last second management opportunity. Montelukest has been approved for many years as a treatment for asthma. And there's very, very impressive research that was recently published indicating that it could be a very effective Alzheimer's treatment. That is very important for the patient because to date there is no treatment available that can reverse the effects of the Alzheimer's disease. That molecule has the potential to do that. And of course, for those of you out there, you may not be aware of this. Are you not the creator and founder of the Listerine script that you put under your tongue? Yes, I am. Or my company is, yeah. All right, so tell our audience what that is and give us the scientific overview on what is Intelligenics technologies and how you were built on this. It's a patent, correct? It is a patent, yeah. So with respect to VersaFilm, I'll answer your question there. You may be familiar with Listerine. We take these films, load them with pharmaceutical active drugs. And the reason why we're doing that is several forms. One is we're increasing the presence of the active in the bloodstream. And as you may imagine, these films are very useful and very easy to take for special needs populations like elderly people, like small children. And finally, films are also, from a business standpoint, a very good tool for life cycle management. And last, not least, they are also a very good business opportunity because film manufacturing is really high-margin business. All right. Well, what I have here, Dr. Duchain, basically was saying the same things. He was just describing this technology as revolutionary when it came out because are there, is there not a different, I think he says, that the quicker for sublingual absorption and that sometimes makes drugs react differently. Is that correct? Sort of, yes. You're very, very correct with your statement that they have the potential to act quicker. The idea is to get an active drug absorbed much faster than that would be the case with a regular tablet. We achieve that with films. And to give you one example that is really useful, take migraine. The film typically delivers the active very quickly to the oral cavity and makes it available for rapid absorption. And that offers the patient the opportunity to suppress the very severe migraine symptoms before they manifest itself. Well, he also was mentioning that there's a potential for reduced adverse effects by bypassing first-past metabolism. I don't know what that means. Can you explain that to me? Yeah, I sure can. When you administer a drug, the conventional way, through a tablet, before the drug reaches the bloodstream, after it migrates through the stomach wall, it passes through the liver and gets metabolized to a time-significant degree. A significant can mean 99%. So that means that only 1% of the drug that you administer by a tablet may reach the bloodstream and become active. If you force the drug to be absorbed in the oral cavity, you bypass this first liver passage and the drug gets directly into the bloodstream. So more drug becomes available for its intended pharmaceutical activity. And of course, Dr. Zerb, in addition to being a visionary and scientist, you're also the CEO of a public company. Can you tell us what we as shareholders should anticipate for the next half a year, a couple upcoming quarters, please? We are in the process of planning a phase-to-age study for our life cycle management product, Montenucas, and that's certainly one of the highlights for the coming months. And we expect from that study a first proof in humans that Montenucas is effective for treatment of Alzheimer's disease. And Dr. Zerb, we know you're incredibly busy changing the world. Thank you so much for joining us today. Thank you very much and thank you for having me.